Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Julie Rothlisberger Castillo

Internal Medicine Omaha, NE Medical Doctor

NPI 1376693374 CMS profile 244215

4220 L St, Suite 100, Omaha, NE 68107

Open in the dashboard

General payments

$64

5 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Julie Rothlisberger Castillo of Omaha, NE is reported in the CMS Open Payments database as having received $64 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 21st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $15 1
2022 General $13 1
2021 General $11 1
2019 General $25 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Rothlisberger Castillo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Julie Rothlisberger Castillo were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Julie Rothlisberger Castillo Internal Medicine median Middle half National median
2019 $25 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $11 $135 $37–$521 $132
2022 $13 $141 $42–$496 $149
2023 $15 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $29 2 payments
  2. Merck Sharp & Dohme Corporation $24 2 payments
  3. GlaxoSmithKline, LLC. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $64 5 payments
Products named General payments · program years 2019–2023
  1. EVENITY $29 2 payments
  2. Prolia $29 2 payments
  3. GARDASIL 9 $24 2 payments
  4. VAXNEUVANCE $24 2 payments
  5. PNEUMOVAX 23 $24 2 payments
  6. VAXELIS $13 1 payment
  7. SHINGRIX $11 1 payment
  8. BEXSERO $11 1 payment
  9. FLULAVAL $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

5,889

Median for Internal Medicine: 777

Drug cost

$439,039

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 68 $76,773
Eliquis Apixaban Brand 90 $73,164
Januvia Sitagliptin Phosphate Brand 68 $70,601
Mounjaro Tirzepatide Brand 52 $56,723
Jardiance Empagliflozin Brand 40 $39,148
Linzess Linaclotide Brand 28 $18,780
Symbicort Budesonide/Formoterol Fumarate Brand 44 $15,302
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $13,595
Spiriva Handihaler Tiotropium Bromide Brand 20 $11,691
Omeprazole Generic 257 $4,433

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$74,694

Of which drugs: $38,874

Medicare patients

117

Average age 69

Services billed

2,303

92 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 33%
Diabetes 32%
Depression 26%
Osteoporosis 24%
Chronic kidney disease 23%
COPD 18%
Ischemic heart disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 1,440 $29,088
Sarscv2 vac 30mcg trs-suc im 91320 Office 31 36 $5,111
Vaccine for influenza for injection into muscle 90653 Office 27 27 $2,209

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record